Patents by Inventor Yip Ching Pui

Yip Ching Pui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20260144756
    Abstract: A fenofibrate composition comprising water soluble chemicals, the composition having a higher dissolution rate in an aqueous medium, wherein the composition is prepared by mixing fenofibrate in an organic solvent solution with an organic acid and other excipients to produce the composition in the form of granules, a tablet or a capsule.
    Type: Application
    Filed: October 20, 2023
    Publication date: May 28, 2026
    Inventors: Yip Ching PUI, Yip Shu PUI, Hing Sang PUI
  • Publication number: 20240315956
    Abstract: The disclosure is directed to the method of production of the composition of a cyclooxygenase-2 (COX-2) inhibitor comprising a water soluble excipient comprising HPMC, an organic acid and one or more other components. The composition may be in the form of pellets, a tablet, a capsule or granules with higher dissolution of the API or fast disintegration in the aqueous medium. In some embodiments, the composition further contains a carbonate salt to form a weakly effervescent disintegration formulation.
    Type: Application
    Filed: July 8, 2022
    Publication date: September 26, 2024
    Inventors: Hing Sang PUI, Yip Ching PUI, Yip Shu PUI
  • Patent number: 11752165
    Abstract: The invention is directed to an intratumor injectable formulation, a method of making the intratumor injectable formulation and a method of treating a malignant mass in a mammal by administering the injectable formulation directly into the malignant mass. The injectable intratumor formulation may be an emulsion, solution or suspension, all of which comprise a therapeutically effective amount of a basic chemotherapeutic drug dissolved or suspended in a biocompatible carrier, wherein the basic chemotherapeutic drug is an anthracycline base, a vina alkaloid base, an eribulin base or an alkylating agent base.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: September 12, 2023
    Assignee: US NANO FOOD & DRUG, INC
    Inventors: Hing Sang Pui, Yip Shu Pui, Yip Ching Pui
  • Publication number: 20210315913
    Abstract: The invention is directed to an intratumor injectable formulation, a method of making the intratumor injectable formulation and a method of treating a malignant mass in a mammal by administering the injectable formulation directly into the malignant mass. The injectable intratumor formulation may be an emulsion, solution or suspension, all of which comprise a therapeutically effective amount of a basic chemotherapeutic drug dissolved or suspended in a biocompatible carrier, wherein the basic chemotherapeutic drug is an anthracycline base, a vina alkaloid base, an eribulin base or an alkylating agent base.
    Type: Application
    Filed: March 30, 2021
    Publication date: October 14, 2021
    Applicant: US NANO FOOD & DRUG, INC
    Inventors: Hing Sang Pui, Yip Shu Pui, Yip Ching Pui